Multi-omics profiling of retinal pigment epithelium reveals enhancer-driven activation of RANK-NFATc1 signaling in traumatic proliferative vitreoretinopathy
简介:
- 作者: Mengyu Liao, Xu Zhu, Yumei Lu, Xiaoping Yi, Youhui Hu, Yumeng Zhao, Zhisheng Ye, Xu Guo, Minghui Liang, Xin Jin, Hong Zhang, Xiaohong Wang, Ziming Zhao, Yupeng Chen & Hua Yan
- 杂志: Nature Communications
- Doi: https://www.doi.org/10.1038/s41467-024-51624-y
- 出版日期: 2024 Aug 25
论文中使用的产品/服务
Quotation shows PackGene:For the gene therapy procedure, rAAV2/2 vectors, rAAV2/2-shNfatc1-Mus-1 (GCCGCAGAACACTACAGTT, AACTGTAGTGTTCTGCGGC) and rAAV2/2-shNfatc1-Mus-2 (GCTCAGAAACTCTGATAT, AATATCAGAGTTTCTGAGC) were obtained from PackGene Biotech and were delivered via a subretinal injection containing 4.9 × 109 viral genome copies in 1 μL volume.
Research Field:vitreoretinopathy
AAV Serotype:AAV2
Targeted organ:eye
Animal or cell line strain:mice
摘要
During the progression of proliferative vitreoretinopathy (PVR) following ocular trauma, previously quiescent retinal pigment epithelial (RPE) cells transition into a state of rapid proliferation, migration, and secretion. The elusive molecular mechanisms behind these changes have hindered the development of effective pharmacological treatments, presenting a pressing clinical challenge. In this study, by monitoring the dynamic changes in chromatin accessibility and various histone modifications, we chart the comprehensive epigenetic landscape of RPE cells in male mice subjected to traumatic PVR. Coupled with transcriptomic analysis, we reveal a robust correlation between enhancer activation and the upregulation of the PVR-associated gene programs. Furthermore, by constructing transcription factor regulatory networks, we identify the aberrant activation of enhancer-driven RANK-NFATc1 pathway as PVR advanced. Importantly, we demonstrate that intraocular interventions, including nanomedicines inhibiting enhancer activity, gene therapies targeting NFATc1 and antibody therapeutics against RANK pathway, effectively mitigate PVR progression. Together, our findings elucidate the epigenetic basis underlying the activation of PVR-associated genes during RPE cell fate transitions and offer promising therapeutic avenues targeting epigenetic modulation and the RANK-NFATc1 axis for PVR management.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。